A gene and its application for the prevention of toxoplasma gondii infection

Abstract

The invention provides a nucleotide sequence for preventing toxoplasma infection. The nucleotide sequences selected from the followings are contained: 1) 724-1470th nucleotide sequences as shown in SEQ ID No.3, and / or 724-2472nd nucleotide sequences as shown in SEQ ID No.1; 2) nucleotide sequences complementary with the nucleotide sequences as shown in 1); and 3) nucleotide sequences which perform substituting, deletion and addition modification on one or a plurality of basic groups of the nucleotide sequences as shown in 1) or 2). The pVAX-CDPK (Calcium Dependent Protein Kinase)1 can effectively prevent and control the infection of a toxoplasma animal model (Kunming mice), and pVAX-IL21-IL15 not only can be independently used for effectively preventing and controlling the toxoplasma infection, but also can be used as a cytokines adjuvant for effectively improving the immune effect of a vaccine pVAX-CDPK1.

Description

Technical field [0001] The present invention relates to the fields of immunology and molecular biology, in particular to a recombinant plasmid used for the prevention of Toxoplasma infection. Background technique [0002] Toxoplasmagondii (T. gondii) is an obligate intracellular parasitic opportunistic pathogenic protozoan, belonging to the Eucoccidiida (Sporozoasida) and Sarcocystidae (Sarcocystidae). The resulting toxoplasmosis is distributed worldwide, and about one-third of people worldwide are infected, seriously endangering the health of humans and animals. As an opportunistic infectious agent, Toxoplasma gondii can cause serious organ damage in immunosuppressed or immunodeficient patients (such as AIDS patients, organ transplantation and malignant tumor patients, etc.). A woman's first infection with Toxoplasma gondii during pregnancy can cause miscarriage, stillbirth, and birth defects or deformities of the fetus and infant. As a zoonotic disease, the impact of toxoplas...

AI Technical Summary

Problems solved by technology

[0003] At present, DNA vaccines have been used against parasites such as: schistosomes, roundworms, especially in protozoa, including Plasmodium, Leishmania, Trypanosoma and other parasites It has been widely used in prevention and treatment, and the vaccine research against Toxoplasma infection has also entered a new stage. However, the research on nucleic acid vaccines against Toxoplasma gondii has not achieved satisfactory results.

The reason is that the life cycle of Toxoplasma gondii is complex, the morphology is diverse, the host range is wide, the immunogens of different antigens are also different, and the pathogenic mechanisms of its cysts and tachyzoites are also different. A vaccine candidate antigen based on a single antigenic component, but it is difficult to form effective resistance against Toxoplasma gondii because it contains few lymphocyte binding sites and the receptor's major histocompatibility complex (Majorhistocompatibility complex, MHC) is highly restrictive Different forms of challenge infection, so it is difficult to achieve the desired effect with only a few candidate antigen genes, and find more and better DNA vaccine candidate antigens from different stages of Toxoplasma gondii, especially those related to the virulence of Toxoplasma gondii The related antigen gene is an important way to study the vaccine against Toxoplasma gondii

Images